Background
==========

Premenstrual dysphoric disorder (PMDD) is a severe and disabling form of premenstrual syndrome (PMS) affecting 1.2--8% (1.2--6.4% \[[@b1-amjcaserep-21-e922797]\] and 3--8% \[[@b2-amjcaserep-21-e922797]\]) of menstruating women. The disease appears to be ovarian hormone-related because physical and psychiatric symptoms only occur during the luteal phases in menstruating women. These symptoms do not occur in females prior to their menarche, during pregnancy, or after menopause. However, no ovarian hormone has been clinically validated as a biomarker for PMDD \[[@b3-amjcaserep-21-e922797]\]. Based on the hypothesis that has been known since the 1980s that PMDD is associated with changing levels of gonadal steroids \[[@b1-amjcaserep-21-e922797]\], ovariectomy or total hysterectomy with bilateral salpingo-oophorectomy has been offered to patients with refractory PMS/PMDD whose condition has failed to respond to all existing treatments \[[@b4-amjcaserep-21-e922797]\]. However, observations of treatment efficacy from such surgical procedures were mainly empirical; their effectiveness and clinical benefits have never been validated with controlled clinical trials. Gibson et al. reported a 10-year follow-up study of patients who underwent surgical menopause including ovarian conservation (N=76) and bilateral oophorectomy (N=101) in whom depression and anxiety scores evaluated and were compared with patients experiencing natural menopause (N=1793). There was no significant clinical benefit from surgical intervention based on statistical analysis, regardless of ovarian retention \[[@b5-amjcaserep-21-e922797]\]. Use of antidepressant medication and hormone therapy was also documented \[[@b5-amjcaserep-21-e922797]\], indicating that symptom-free status was not commonly achieved with surgical procedures alone. A similar study has never been done among patients with PMS/PMDD who chose to have ovariectomy as intervention.

We report the case of a patient with chronic PMS/PMDD-like symptoms for more than 20 years, and who had a coexistent pituitary adenoma that was found in 2016 by brain magnetic resonance imaging (MRI). She underwent transsphenoidal surgery (TSS) in December 2017 when the tumor was found to be larger with follow-up MRIs, and had met criteria for surgical intervention ([Figure 1](#f1-amjcaserep-21-e922797){ref-type="fig"}). The goal of the surgery was to achieve accurate diagnosis and to prevent optic chiasm compression. Surprisingly, the patient experienced dramatic improvement in her PMDD-like symptoms after surgery. To our knowledge, this is the first case report of remission of PMS/PMDD-like symptoms after TSS.

Case Report
===========

The patient, a 44-year-old woman, was first diagnosed with major depression in 1997 while she was still residing in China. Physical symptoms included delayed and irregular menstruation, bloating, and chest tightness in a cyclical pattern that had persisted for more than 20 years. She gave birth to three healthy children and did not experience such symptoms during her pregnancies, but the symptoms returned postpartum and were accompanied by severe weight loss after her third delivery ([Figure 1A](#f1-amjcaserep-21-e922797){ref-type="fig"}). These monthly recurring symptoms occurred about 5--10 days prior to the patient's menses, and completely resolved with the onset of her period. After she was diagnosed with major depression by her psychiatrist in China, she was prescribed selective serotonin reuptake inhibitors (SSRI), but the patient did not benefit from these medications.

The patient experienced persistent intermittent psychiatric symptoms including depressed mood, anxiety, anger, self-blame, and suicidal ideation with attempts. Initially, agoraphobia and social avoidance were noted, but these symptoms resolved 5 to 6 years later. Subsequently, she developed cyclic chest tightness that worsened over the years. With the onset of symptoms, she also exhibited self-destructive behaviors, such as head-banging against walls or hitting her head with her hands intermittently. These behaviors were unassociated with headache, nausea, or vomiting. The patient developed suicidal thoughts and attempted suicide a few times around the year 2010, but did not have suicidal ideation during the 5 years prior to TSS. She denied cold or heat intolerance, thirst, or hair loss. Physical and neurological exams were within normal limits except for a highly anxious state and severely reduced self-confidence and tendency to self-blame. Thyroid function evaluated multiple times showed results within normal limits. Repeated medical check-ups showed no evidence of hypertension, cardiac ischemia, electrocardiographic abnormalities, or tachycardia, that could have contributed to the complaints of chest tightness. The patient has never used tobacco, alcohol, or illegal drugs. Her family history is positive only for maternal hyperthyroidism.

The patient was initially seen in the neuro-oncology clinic in 2016 because of galactorrhea. Laboratory results showed a prolactin (PRL) level of 35.9 ng/mL ([Table 1](#t1-amjcaserep-21-e922797){ref-type="table"}). Brain MRI with contrast revealed a solid pituitary lesion. She was prescribed bromocriptine (2.5 mg once daily). Her PRL level rose to 50.8 ng/mL once while on bromocriptine, and subsequently returned to within the normal range ([Table 1](#t1-amjcaserep-21-e922797){ref-type="table"}). The patient's galactorrhea responded quickly to bromocriptine, and her monthly symptoms were also significantly improved. Typical PMDD symptoms reappeared in October 2017. A diagnosis of PMDD was made based on recurrent monthly symptoms, including sudden feelings of sadness and crying, markedly depressed mood, and markedly increased interpersonal conflicts with family members ([Figure 1A](#f1-amjcaserep-21-e922797){ref-type="fig"}).

Repeat brain MRI showed a pituitary adenoma with increased size that met the criteria for surgical intervention ([Figure 1B](#f1-amjcaserep-21-e922797){ref-type="fig"}). Visual acuity in the patient's right eye was worse than left eye, but that had been stable over the last 10 years without optic nerve compression or peripheral vision loss. She declined to have visual acuity or visual field testing by an ophthalmologist. The patient was sent to an emergency room two weeks prior to the scheduled surgery because of sudden onset of chest tightness, but no cause was found for the symptoms, or for evidence of myocardial ischemia. Elective TSS was performed on December 28, 2017 and the pathological diagnosis was a nonfunctioning pituitary adenoma (NFPA). She tolerated the TSS well without any complication, and a gross total resection of the pituitary adenoma was achieved.

The patient has been followed for 28 months at the time of writing of this report. Her menstrual cycles became normal and regular ([Table 2](#t2-amjcaserep-21-e922797){ref-type="table"}) after TSS and she was completely symptom-free during months 1 to 3, 8, 10, 12 to 18, and 20 to 28 without taking medication. She had sporadic episodes of chest tightness and anxiety during postoperative months 4 to 7, 9, 11 and 19. These symptoms did not have the same temporal relationship with the patient's menses, and the symptoms were mild and short-lived. She does not drink coffee regularly, but happened to drink it a couple of times at work after she recovered from the TSS. A few hours after drinking coffee she reported mild anxiety and chest tightness, which resolved completely in 3 to 5 days. She developed two more episodes of mild anxiety and chest tightness; one was after watching a scary movie trailer in month 9, and the other episode was after one red-eye flight in month 19 post-TSS ([Table 2](#t2-amjcaserep-21-e922797){ref-type="table"}). The patient did take vortioxetine (5 mg) samples once a day for 2 weeks during the 7^th^ month post-TSS, but she chose to discontinue the medication. She has returned to a normal life, and has been free of PMDD symptoms for a 9-month period without medications.

Discussion
==========

We report a case of a menstruating patient with full remission of PMDD symptoms after resection of a NFPA. This patient was first diagnosed with major depression in 1997, prior to the formal adoption of PMDD in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V 2013) \[[@b1-amjcaserep-21-e922797]\]. Her medical/psychiatric symptoms and their duration met the diagnostic criteria for PMDD. We describe her symptoms as PMDD-"like" because the diagnosis was not made by a psychiatrist, and it was a retrospective diagnosis. Based on psychiatric studies of major depressive disorders, in which a "full remission" is defined as a return of and sustained normal functioning for 4 to 6 months \[[@b6-amjcaserep-21-e922797]\], the patient's recovery met this definition. Most recently, she has achieved a symptom-free status for 9 months consecutively, with regular menstrual cycles. Although she has experienced recurrent episodes of mild anxiety and chest tightness associated with coffee consumption, scary movies, and a late-night flight, she recovered from these symptoms within 3 to 5 days without further medical intervention.

In this patient, a pituitary mass was identified during evaluation for galactorrhea. Her PRL level was slightly elevated ([Table 1](#t1-amjcaserep-21-e922797){ref-type="table"}), but it did not meet the current diagnostic criteria for prolactinoma (PRL ≥250 µg/L). A stalk effect \[[@b7-amjcaserep-21-e922797]\] rather than a true prolactin-secreting adenoma is quite possible, and pathological findings confirmed the pituitary lesion to be a NFPA. A literature search revealed similar cases. For example, one 32-year-old patient with PMS/PMDD with an initial PRL level of 48.1 µg/L was found to have a co-existing "micro-prolactinoma" (8×4 mm), which was stable in size during a 17-month follow-up \[[@b8-amjcaserep-21-e922797]\]. Although the elevated PRL was successfully suppressed with cabergoline, the patient continued having cyclical mood fluctuations described as "2 weeks of normal mood followed by a week of depressed mood with hypersomnia, anorexia, and fatigue, and then a week of hypomanic symptoms" \[[@b8-amjcaserep-21-e922797]\]. This is a typical description of PMS/PMDD.

Elevated intrasellar pressure (ISP) is known to occur in patients who have pituitary lesions, and it has been suggested as a cause for the clinical symptoms as the symptoms resolve after surgical reduction of ISP \[[@b9-amjcaserep-21-e922797],[@b10-amjcaserep-21-e922797]\]. Elevated pressure on the pituitary gland, either indirectly from increased intracranial pressure, or directly from cerebrospinal fluid leaking into the pituitary fossa, is a known cause for the empty sella syndrome (ESS). Contrary to the common belief that ESS is usually asymptomatic, two early studies of 43 \[[@b11-amjcaserep-21-e922797]\] and 71 \[[@b12-amjcaserep-21-e922797]\] cases reported a high frequency of psychological disorders \[[@b11-amjcaserep-21-e922797]\] and 80.2% \[[@b12-amjcaserep-21-e922797]\] of mental disorders, respectively. A literature search exploring the occurrence of psychiatric symptoms that may predate the objective pituitary findings, depression was reported in 71% of relevant papers \[[@b13-amjcaserep-21-e922797]\]. On average, it took 11 years from initially documented clinical depression to an objective pituitary abnormality among 51% of cases with pituitary findings \[[@b13-amjcaserep-21-e922797]\].

Encouragingly, studies of psychiatric symptoms associated with NFPA are now getting some needed attention \[[@b14-amjcaserep-21-e922797]\]. For example, one study demonstrated that patients with NFPA (N=58) have increased anxiety-related personality traits compared to 140 age- and gender-matched, mentally healthy population controls \[[@b15-amjcaserep-21-e922797]\]. A NFPA has been noted in a PMDD patient \[[@b8-amjcaserep-21-e922797]\], and in a woman with major depression \[[@b16-amjcaserep-21-e922797]\]. Complete remission of major depression was also reported after surgical removal of the lesion \[[@b16-amjcaserep-21-e922797]\].

Stalk effect from pituitary gland may be a dynamic phenomenon. It is not necessarily absent in patients with normoprolactinemia \[[@b7-amjcaserep-21-e922797]\]. Based on such observations, surgery may be a better treatment option than pharmaceutical agents because surgical removal of a lesion will eliminate the stalk effect \[[@b8-amjcaserep-21-e922797]\] and/or elevated ISP \[[@b9-amjcaserep-21-e922797],[@b10-amjcaserep-21-e922797]\]. Surgical removal of NFPA and drainage of cysts have been demonstrated to provide durable normalization of serum PRL levels and to achieve significant symptom reduction or resolution \[[@b7-amjcaserep-21-e922797],[@b14-amjcaserep-21-e922797]\]. Unfortunately, no study has ever been conducted regarding the long-term effects of pituitary gland surgery on psychiatric/psychological outcomes.

The exact pathophysiology of and factors contributory to PMS/PMDD remain elusive. For example, studies on an association between coffee consumption and PMS are inconclusive \[[@b17-amjcaserep-21-e922797],[@b18-amjcaserep-21-e922797]\]. Interestingly, the patient in this case had two episodes of anxiety and/or chest tightness soon after coffee consumption, and similar episodes after a red-eye domestic flight. Because she suffered PMDD for more than 20 years, her reaction threshold to such stimuli may be lower than normal. It is also possible that chemicals such as caffeine, or a change in fear-related internal neurotransmitter(s) trigger a neural cascade, which leads to different psychiatric symptoms.

Based on what we observed in this case, we propose a model in which pituitary hormone secretion is not thought to be the key factor causing PMS/PMDD symptoms ([Figure 2](#f2-amjcaserep-21-e922797){ref-type="fig"}). Rather, we speculate that some neurotransmitters indirectly affected by either the stalk effect or elevated ISP may have causative roles. This patient's symptoms can still be triggered by coffee and other stimuli (scary movies) after months free of symptoms, which indicates that an etiopathogenetic neurotransmitter cascade still gets activated when the inciting stimulus presents. The pituitary gland receives neurotransmitters from the hypothalamus, and in young women, its size changes during each menstrual cycle \[[@b19-amjcaserep-21-e922797],[@b20-amjcaserep-21-e922797]\]. If there is a space-occupying pituitary adenoma within the sella turcica, physiological change in size or length of a normal pituitary gland during each menstrual cycle will be restricted. Given the impact of a space-occupying lesion, a distorted hypophyseal gland body or stalk reduces or blocks transmission of neurotransmitter(s) coming down from the hypothalamus or other anatomic connections. Imbalanced neurotransmitter(s) subsequently result in PMS/PMDD symptoms. When the pituitary gland's size returns to its baseline during the follicular phase, a patient's PMS/PMDD symptoms are reduced or resolved as long as the sella can still hold both pituitary gland and a small space-occupying mass. With this model, clinical benefits might reasonably be expected after surgical removal of mass lesion. However, the model would not explain the absence of PMS/PMDD during pregnancy despite the fact that the pituitary gland enlarges throughout pregnancy as a physiological process \[[@b21-amjcaserep-21-e922797],[@b22-amjcaserep-21-e922797]\].

Evidence is lacking at this time on the benefits of surgical treatment of NFPA in patients with psychiatric disorders. As a result, we cannot draw any firm conclusions; however, this case report along with prior evidence of psychiatric disease in patients with NFPA supports a possible link. Therefore, we recommend that physicians use brain MRI to assess for possible pituitary lesions in patients with refractory PMS/PMDD. For patients with PMS/PMDD who have a comorbid pituitary lesion, surgery should be considered, with postoperative monitoring and evaluation of PMS/PMDD symptoms. Identification of additional cases like the one presented here may facilitate classification of PMS/PMDD with comorbid pituitary lesion as a subtype of PMS/PMDD.

Conclusions
===========

Surgical resection of NFPA resulted in immediate relief and durable remission of PMDD symptoms as demonstrated in this case. This observation suggests that a NFPA or another space-occupying lesion in the sella, either due to stalk effect or elevated ISP, may play a contributory role in PMDD. A brain MRI scan with and without contrast should be considered in screening patients with refractory PMS/PMDD. Prospective studies should investigate whether a pituitary lesion may cause or indirectly contribute to PMS/PMDD and surgical intervention might be of benefit in these patients.

![History of PMDD symptoms of in a woman and her pre- and post-TSS brain MRI images. (**A**) Summary of medical history and PMDD symptoms prior to and post-TSS. (**B**) A series of MRIs demonstrated that the size of the mass changed from 1.05 (CC)×1.07 (AP) cm at initial diagnosis (7/11/2016) to 1.3×1.13 cm in 15 months (10/30/2017). The **bottom panel** shows an MRI (04/02/2018) taken 3 months post-TSS. Coronal and sagittal view images with contrast for each time period are provided.](amjcaserep-21-e922797-g001){#f1-amjcaserep-21-e922797}

![A proposed pathophysiological model for cyclic PMS/PMDD symptoms. The size of a normal functional pituitary gland changes during each menstrual cycle, but the extent of the change is limited or restricted by a NFPA (lesion is not drawn in the figure) or other types of space-occupying lesions. A distorted gland body or its stalk may reduce or even block the action of neurotransmitter(s) that originate from the hypothalamus or other anatomical connections. PMS/PMDD symptoms occur due to a delicate imbalance within the brain. When the size of the pituitary gland returns to baseline during the follicular phase, PMS/PMDD symptoms are also resolved while neurotransmitter transport is restored.](amjcaserep-21-e922797-g002){#f2-amjcaserep-21-e922797}

###### 

Relevant lab results prior to and post-pituitary adenoma diagnosis and TSS.

  **Date**         **7/8/16**   **9/7/16**   **4/3/17[^\*^](#tfn1-amjcaserep-21-e922797){ref-type="table-fn"}**   **11/6/17**   **12/13/17**   **12/18/17**   **1/5/18**   **1/19/18**   **7/5/18**   **Normal range**
  ---------------- ------------ ------------ -------------------------------------------------------------------- ------------- -------------- -------------- ------------ ------------- ------------ ---------------------
  **TSH**          2.17         2.68                                                                              4.51 H                       1.34           1.48                       2.96         0.36--3.74 mIU/mLmL
  **T4**           7.8          10.0                                                                                                           10.4                                                   4.7--13.3 ug/dL
  **Free T4**      0.85         0.94                                                                              0.88                         1.05           0.9                        1.01         0.76--1.46 ng/mLmL
  **T3 total**                                                                                                                                 1.25                                                   0.6--1.81 ng/mLmL
  **T3 uptake**    35           29 L                                                                                                           31                                                     31--39%
  **Free T3**                                                                                                                                  2.98                                                   2.18--3.98 pg/mLmL
  **FSH**          6.2          7.1                                                                               7.9                          6.2            5.3                                     3--20 mIU/mLmL
  **LH**           8.52         6.61                                                                              13.65                        3.58           3.6                                     2--15 mIU/mLmL
  **Prolactin**    35.9 H       50.8 H                                                                            10.8                         20.6           6.1                        8.2          2.8--29.2 ng/mLmL
  **ACTH**         11                                                                                             8                            20                                                     0--46 pg/mLmL
  **Cortisol**                                                                                                    3                            11.2           8.5                                     6--23 ug/dL
  **UFC**                                                                                                         28                                                                                  0--50 ug/24h
  **Estradiol**                                                                                                   54.9                                                                                19.5--144.2 pg/mLmL
  **GH**                                                                                                                                       0.1                         \<0.1                      0--8 ng/mLmL
  **IGF-I**                                                                                                       154                          198            206 H        146           201          62--204 ng/mLmL
  **Total CK**                                                                                                                  114                                                                   12--191 U/L
  **CK-MB**                                                                                                                     \<1.0                                                                 0.5--3.6 ng/mLmL
  **Troponin-I**                                                                                                                \<0.02                                                                0.00--0.40 ng/mLmL
  **NMN**                                                                                                                                                                                48           0--145 pg/mLmL
  **MN**                                                                                                                                                                                 24           0--62 pg/mLmL
  **TSH**                                    2.72                                                                                                                                                     0.3--4.6 mIU/L
  **Free T4**                                13.75                                                                                                                                                    10.29--21.88 pmol/L
  **Free T3**                                5.01                                                                                                                                                     3.39--6.47 pmol/L
  **Prolactin**                              69.46                                                                                                                                                    55--760 mIU/L
  **TGAb**                                   6.68                                                                                                                                                     5--100 IU/mLmL
  **TPOAb**                                  7.42                                                                                                                                                     1--20 IU/mLmL
  **TRAb**                                   Negative                                                                                                                                                 

Lab test was from outside the hospital. H -- high; ACTH -- adrenocorticotropic hormone; CK-MB -- creatine kinase-muscle/brain isoform; FSH -- follicle-stimulating hormone; GH -- growth hormone; IGF -- insulin-like growth factor; LH -- luteinizing hormone; MN -- metanephrine; NMN -- normetanephrine; T3 -- triiodothyronine; T4 -- thyroxine; TGAb -- thyroglobulin antibody; TPOAb -- thyroid peroxidase antibody; TRAb -- thyrotropin receptor antibody; UFC -- urine 24 free cortisol.

###### 

Summary of symptoms during the 28 months follow up post-TSS.

  **Months**   **Menstrual cycle post-TSS in days[^\*^](#tfn2-amjcaserep-21-e922797){ref-type="table-fn"}**   **Symptoms[^\*\*^](#tfn3-amjcaserep-21-e922797){ref-type="table-fn"}**   **Medication**                     **Notes**
  ------------ ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------- -------------------------------------------
  1            [^\*\*\*^](#tfn4-amjcaserep-21-e922797){ref-type="table-fn"}                                                                                                                                               
  2            34                                                                                                                                                                                                         
  3            31                                                                                                                                                                                                         
  4            35                                                                                             Chest tightness, anxiety                                                                                    After coffee
  5            28                                                                                             Chest tightness                                                                                             
  6            31                                                                                             Chest tightness                                                                                             
  7            26                                                                                             Chest tightness, anxiety                                                 Vortioxetine 5 mg (2 weeks only)   
  8            28                                                                                                                                                                                                         
  9            32                                                                                             Chest tightness, anxiety                                                                                    Fear after watching a scary movie trailer
  10           35                                                                                                                                                                                                         
  11           24                                                                                             Anxiety                                                                                                     After coffee
  12--18       27--32                                                                                                                                                                                                     
  19           29                                                                                             Anxiety                                                                                                     After a red-eye domestic flight
  20--28       28--32                                                                                                                                                                                                     

Menstrual cycle (days) is calculated by counting the days from Day 1 of one cycle to the next;

these symptoms occurred randomly, without any relationship to the patient's menses and were less severe than her symptoms prior to TSS;

no data on previous period prior to her TSS. First period started 19 days after surgery, which was on 12/28/2017. TSS -- transsphenoidal surgery.
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